1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
September 28, 2022
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
August 22, 2022
Resverlogix Announces Appointment of New Chief Scientific Officer
August 15, 2022
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
June 21, 2022
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
June 21, 2022
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
June 8, 2022
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
May 9, 2022
Resverlogix Announces One-Year Extension of Debenture
April 19, 2022
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
March 17, 2022
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
February 17, 2022
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
January 18, 2022